CO99 Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Utilization Patterns for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Among United States (US) Community Hematologists/Oncologists (CH/OS)
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.195
https://www.valueinhealthjournal.com/article/S1098-3015(22)00396-5/fulltext
Title :
CO99 Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Utilization Patterns for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Among United States (US) Community Hematologists/Oncologists (CH/OS)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00396-5&doi=10.1016/j.jval.2022.04.195
First page :
Section Title :
Open access? :
No
Section Order :
10165